Analgesic Ketamine for Battlefield Use
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DEFENSE HEALTH AGENCY
Contract Value
Not provided
Codes & Classification
Solicitation Number
HT9427-26-RFI-701
NAICS
-
Classification Code
-
Additional Details
Documents2
The Defense Health Agency (DHA), through its Office of the Principal Medical Executive (OPMED) Warfighter Performance and Acute Care (WPAC) Program Management Office (PMO), has issued a Sources Sought notice to gather information from industry regarding the development of an analgesic ketamine product for battlefield use. This market research initiative is aimed at identifying potential collaborators capable of developing, manufacturing, and securing U.S. Food and Drug Administration (FDA) approval for a ketamine-based solution specifically designed to address acute severe pain resulting from battlefield injuries, in alignment with Tactical Combat Casualty Care (TCCC) protocols.
The scope of this procurement encompasses all forms of ketamine products suitable for administration in combat environments. The DHA is open to considering a wide range of delivery mechanisms, including but not limited to autoinjectors, oral capsules, pumps, topical creams, and patches. The intent is to identify solutions that can be rapidly and effectively deployed in the field to manage severe pain, thereby improving outcomes for injured service members.
Key requirements for this opportunity include the ability to collaborate with the government on product development, manufacturing, and regulatory approval processes. The selected solution must ultimately achieve FDA approval, ensuring safety and efficacy for battlefield use. While the current notice is a Request for Information (RFI) and not a solicitation, the DHA anticipates releasing a formal Request for Proposals (RFP) for the analgesic ketamine product in Fiscal Year 2026.
This procurement is not subject to any set-aside restrictions, making it open to all qualified entities. The place of performance is Maryland, United States, and the contracting activity is managed by the Defense Health Agency, a federal office. Interested parties are encouraged to review the attachments provided with the notice for additional instructions and details.
For further information or to submit a response, contractors may contact Jeanette Collins ([email protected]) or Shannon Lertora ([email protected]). The notice remains active, with responses due by January 12, 2026. Additional details and updates can be accessed via the official SAM.gov opportunity page at https://sam.gov/opp/fd09328814b04d5ab49e6869fa56df38/view.
This opportunity is particularly relevant for organizations with expertise in pharmaceutical development, regulatory affairs, and battlefield medical solutions, and who are capable of supporting the DHA’s mission to enhance combat casualty care through innovative pain management products.